BR112018068314A2 - célula imunocompetente e vetor de expressão que expressam fatores regulatórios de função imunológica - Google Patents

célula imunocompetente e vetor de expressão que expressam fatores regulatórios de função imunológica

Info

Publication number
BR112018068314A2
BR112018068314A2 BR112018068314A BR112018068314A BR112018068314A2 BR 112018068314 A2 BR112018068314 A2 BR 112018068314A2 BR 112018068314 A BR112018068314 A BR 112018068314A BR 112018068314 A BR112018068314 A BR 112018068314A BR 112018068314 A2 BR112018068314 A2 BR 112018068314A2
Authority
BR
Brazil
Prior art keywords
cell
immune function
immunocompetent
expression vector
immunocompetent cell
Prior art date
Application number
BR112018068314A
Other languages
English (en)
Inventor
ADACHI Keishi
Tamada Koji
Sakoda Yukimi
Original Assignee
Univ Yamaguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yamaguchi filed Critical Univ Yamaguchi
Publication of BR112018068314A2 publication Critical patent/BR112018068314A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

a presente invenção refere-se a uma célula imunocompetente que expressa os fatores de regulação da função imune de célu-las imunocompetentes e possui todo o potencial proliferativo, viabilidade e capacidade para acumular uma célula t e um vetor de expressão de fatores de regulação da função imune com a finalidade de gerar a célula imunocompetente. uma célula imunocompetente que expressa uma molécula de superfície da célula que reconhece de maneira específica um antígeno de câncer, interleucina 7 (il-7) e ccl19 é gerada. de uma maneira preferida, a molécula da superfície da célula que reconhece de maneira específica um antígeno de câncer é o receptor de células t que reconhece de maneira específica o antígeno de câncer, e a célula imunocompetente uma célula t.
BR112018068314A 2016-03-17 2017-03-15 célula imunocompetente e vetor de expressão que expressam fatores regulatórios de função imunológica BR112018068314A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016053913 2016-03-17
PCT/JP2017/010437 WO2017159736A1 (ja) 2016-03-17 2017-03-15 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター

Publications (1)

Publication Number Publication Date
BR112018068314A2 true BR112018068314A2 (pt) 2019-01-15

Family

ID=59851517

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068314A BR112018068314A2 (pt) 2016-03-17 2017-03-15 célula imunocompetente e vetor de expressão que expressam fatores regulatórios de função imunológica

Country Status (18)

Country Link
US (2) US11337997B2 (pt)
EP (1) EP3431597A4 (pt)
JP (4) JP6561372B2 (pt)
KR (3) KR102186180B1 (pt)
CN (2) CN109153989B (pt)
AU (1) AU2017235116B2 (pt)
BR (1) BR112018068314A2 (pt)
CA (1) CA3017442A1 (pt)
IL (1) IL261707A (pt)
MX (2) MX2018010974A (pt)
MY (1) MY190565A (pt)
NZ (1) NZ746168A (pt)
PH (1) PH12018550156A1 (pt)
RU (1) RU2770812C2 (pt)
SG (1) SG11201807857PA (pt)
TW (2) TW202313966A (pt)
WO (1) WO2017159736A1 (pt)
ZA (1) ZA201805913B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11337997B2 (en) * 2016-03-17 2022-05-24 Yamaguchi University Immunocompetent cell and expression vector expressing regulatory factors of immune function
CA3048312A1 (en) 2017-01-01 2018-07-05 Chi-Yu Gregory Lee Rp215 chimeric antigen receptor construct and methods of making and using same
WO2018181207A1 (ja) * 2017-03-27 2018-10-04 ノイルイミューン・バイオテック株式会社 キメラ抗原受容体
IL305898A (en) 2017-10-10 2023-11-01 Univ Yamaguchi Boosts T-cells or B-cells with memory activity, suppresses recurrent malignant growth and boosts memory activity in T-cells or B-cells
SG11202005908WA (en) 2017-12-24 2020-07-29 Noile Immune Biotech Inc Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19
SG11202011392VA (en) * 2018-05-15 2020-12-30 Carsgen Therapeutics Co Ltd Genetically engineered cell and application thereof
KR20220092543A (ko) * 2019-10-28 2022-07-01 노일 이뮨 바이오테크 가부시키가이샤 암의 치료를 위한 의약, 조합 의약, 의약 조성물, 면역 응답성 세포, 핵산 전달 비히클 및 제품
CN111849910B (zh) 2020-05-27 2021-06-15 南京北恒生物科技有限公司 工程化免疫细胞及其用途
TW202317634A (zh) 2021-07-16 2023-05-01 日商諾伊爾免疫生物科技股份有限公司 抗ＥＧＦＲｖｉｉｉ抗體、多肽、表現前述多肽之細胞、含有前述細胞之醫藥組成物、前述細胞之製造方法、及含有編碼前述多肽之鹼基序列之聚核苷酸或載體
WO2023286841A1 (ja) 2021-07-16 2023-01-19 ノイルイミューン・バイオテック株式会社 キメラ抗原受容体、前記受容体を発現する細胞、前記細胞を含む医薬組成物、前記細胞の製造方法、及び、前記キメラ抗原受容体をコードする塩基配列を含むポリヌクレオチド又はベクター
CN117642421A (zh) * 2021-07-29 2024-03-01 武田药品工业株式会社 特异性靶向间皮素的工程化免疫细胞以及其用途
CN115704010A (zh) * 2021-08-11 2023-02-17 南京北恒生物科技有限公司 工程化免疫细胞及其用途
GB202205572D0 (en) 2022-04-14 2022-06-01 Adaptimmune Ltd Engineered T cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009302804B2 (en) * 2008-10-08 2015-07-02 Intrexon Corporation Engineered cells expressing multiple immunomodulators and uses thereof
WO2011119773A1 (en) 2010-03-23 2011-09-29 Roeth Jeremiah F Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
JP5947311B2 (ja) 2010-12-09 2016-07-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用
CA2821080C (en) * 2010-12-14 2021-02-02 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
CN102539745B (zh) * 2010-12-31 2013-03-06 中国人民解放军第三〇九医院 移植肾排斥反应早期诊断及预警试剂盒
WO2013040371A2 (en) * 2011-09-16 2013-03-21 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
JP6117515B2 (ja) 2011-11-01 2017-04-19 国立大学法人名古屋大学 髄膜腫治療用医薬組成物
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CA2867487C (en) * 2012-03-21 2021-02-02 Dana-Farber Cancer Institute, Inc. Isolation and use of human lymphoid organ-derived suppressive stromal cells
CA2962375C (en) * 2014-10-09 2020-07-14 Yamaguchi University Car expression vector and car-expressing t cells
US11337997B2 (en) * 2016-03-17 2022-05-24 Yamaguchi University Immunocompetent cell and expression vector expressing regulatory factors of immune function
CN112226462A (zh) * 2020-10-12 2021-01-15 广东昭泰体内生物医药科技有限公司 共表达分泌型il-7和选择性ccl19的表达载体及其应用

Also Published As

Publication number Publication date
RU2018135652A3 (pt) 2020-08-24
KR20180127403A (ko) 2018-11-28
JPWO2017159736A1 (ja) 2019-01-31
KR102186180B1 (ko) 2020-12-03
US20190099446A1 (en) 2019-04-04
JP2019154455A (ja) 2019-09-19
TW202313966A (zh) 2023-04-01
ZA201805913B (en) 2019-07-31
NZ746168A (en) 2022-04-29
US11931381B2 (en) 2024-03-19
US11337997B2 (en) 2022-05-24
RU2018135652A (ru) 2020-04-17
TW201734205A (zh) 2017-10-01
JP7479082B2 (ja) 2024-05-08
MX2023005317A (es) 2023-05-19
KR20230017358A (ko) 2023-02-03
TWI789348B (zh) 2023-01-11
JP2021121198A (ja) 2021-08-26
US20220273723A1 (en) 2022-09-01
JP6561372B2 (ja) 2019-08-21
JP6884423B2 (ja) 2021-06-09
EP3431597A1 (en) 2019-01-23
CN109153989A (zh) 2019-01-04
AU2017235116B2 (en) 2019-11-07
EP3431597A4 (en) 2019-11-13
AU2017235116A1 (en) 2018-10-11
WO2017159736A1 (ja) 2017-09-21
RU2770812C2 (ru) 2022-04-22
KR102495308B1 (ko) 2023-02-06
CN115896120A (zh) 2023-04-04
CA3017442A1 (en) 2017-09-21
JP2023029553A (ja) 2023-03-03
MY190565A (en) 2022-04-27
SG11201807857PA (en) 2018-10-30
MX2018010974A (es) 2019-03-28
PH12018550156A1 (en) 2019-03-04
CN109153989B (zh) 2022-10-28
IL261707A (en) 2018-10-31
KR20200137030A (ko) 2020-12-08

Similar Documents

Publication Publication Date Title
BR112018068314A2 (pt) célula imunocompetente e vetor de expressão que expressam fatores regulatórios de função imunológica
BR112017006710A2 (pt) vetor de expressão de car e células t expressando car
BR112018013663A2 (pt) proteínas quiméricas e métodos de imunoterapia
BR112018013074A2 (pt) terapias de célula efetora imune com eficácia real-çada
WO2018064594A3 (en) Hla class i-deficient nk-92 cells with decreased immunogenicity
CO2019000946A2 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
EA201790624A1 (ru) Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии
CL2018002828A1 (es) Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores.
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
EA202190709A1 (ru) Универсальные донорские клетки
BR112018012180A2 (pt) vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
CO2017006808A2 (es) Receptores de antígenos quiméricos de bcma
BR112017018770A2 (pt) redução da tolerância imunológica induzida por pd-l1
BR112018002600A2 (pt) células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38
WO2018023025A8 (en) RECEPTOR POLYTHERAPIES OF CHIMERIC ANTIGENS DNA PD INHIBITORS -1
UY37155A (es) Inhibidores de ret
BR112018067698A2 (pt) células modificadas para imunoterapia
AU2017259987A1 (en) Intracellular delivery of biomolecules to induce tolerance
TR201819571T4 (tr) Hem immün hücrelerde hem de patolojik hücrelerde bulunan antijenleri hedef almak amacıyla değiştirilmiş immünoterapiye yönelik hücreler.
BR112017001183A2 (pt) tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
BR112018003535A2 (pt) receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão
CY1122612T1 (el) Μεθοδος
MY193723A (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
UY35964A (es) Anticuerpos humanos para pd?1
PE20191847A1 (es) Receptores de antigenos quimericos que se dirigen a flt3

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]